Nasdaq:US$16.94 (-0.01) | HKEX:HK$26.65 (-0.20) | AIM:£2.80 (+0.02)
News & Presentations
Previous Article   |   Next Article
Announcements & Press Releases, Regulatory Notice | 29 Jun 2015

Blocklisting Six Monthly Return

London: Monday, 29 June 2015: Hutchison China MediTech Limited (“Chi-Med”) (AIM: HCM)announces the following blocklisting six monthly return:


Name of applicant:

Hutchison China MediTech Limited


Name of scheme:

Hutchison China MediTech Limited Share Option Scheme


Period of return:

From 29 December 2014 to 28 June 2015


Balance under scheme from previous return:

696,051 ordinary shares of US$1 each


The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:



Number of securities issued/allotted under scheme during period:

223,288 ordinary shares of US$1 each


Balance under scheme not yet issued/allotted at end of the period:

472,763 ordinary shares of US$1 each


Number and class of securities originally listed and the date of admission:

2,560,606 ordinary shares of US$1 each admitted on 26 June 2007


Total number of securities in issue at the end of the period:

53,299,964 ordinary shares of US$1 each

Name of contact:

Christian Hogg

Address of contact:

21/F., Hutchison House, 10 Harcourt Road, Hong Kong

Telephone number of contact:

+852 2121 8200




Christian Hogg, CEO

Telephone: +852 2121 8200

Panmure Gordon (UK) Limited

Telephone: +44 20 7886 2500

Richard Gray

Andrew Potts

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 20 7638 9571

Mobile: +44 7973 611 888

Mobile: +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK:1). For more information, please visit:

1 items